Oral Contraceptives in Dermatology

Area of Science:

• Dermatology
• Endocrinology
• Pharmacology

Background:

• Oral contraceptives (OCs) combine estrogen and progesterone to inhibit ovulation.
• In dermatology, OCs are prescribed for pregnancy prevention during teratogenic drug use and to manage hyperandrogenism.
• While generally beneficial for acne and hirsutism, certain progestogens in OCs can worsen acne.

Purpose of the Study:

• To review the dermatological applications of oral contraceptives.
• To discuss the selection criteria for OCs based on therapeutic goals and potential side effects.
• To highlight the balance between contraceptive efficacy, dermatological benefits, and risks.

Main Methods:

• Literature review of studies on oral contraceptives in dermatology.
• Analysis of hormonal components (estrogen and progestogen) and their effects.
• Evaluation of side effect profiles, particularly thrombosis and androgenic effects.

Main Results:

• Estrogen dose is a primary factor in the thrombotic risk of OCs.
• Levonorgestrel combined with ≤30μg ethinyl estradiol is recommended for favorable thrombotic profiles.
• Progestogens with antiandrogenic properties are preferred for treating androgenization symptoms.

Conclusions:

• Oral contraceptive choice in dermatology requires careful consideration of both benefits and risks.
• Tailoring OC selection to individual patient needs, such as managing hyperandrogenism or minimizing thrombotic risk, is essential.
• Understanding the progestogen and estrogen components is key to optimizing OC therapy in dermatological practice.